Perfusion CT imaging of brain tumors: An overview

American Journal of Neuroradiology

Volumn 32, Issue 9, 2011, Pages 1570-1577

  Jain, R ^a  

^a HENRY FORD HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANGIOGENESIS; BLOOD VESSEL PERMEABILITY; BLOOD VOLUME; BRAIN TUMOR; CANCER GRADING; COMPUTER ASSISTED TOMOGRAPHY; DIFFERENTIAL DIAGNOSIS; GLIOMA; HUMAN; PERFUSION COMPUTED TOMOGRAPHY; PERFUSION WEIGHTED IMAGING; PROGNOSIS; REVIEW; SCINTIGRAPHY;

ADULT; BRAIN NEOPLASMS; FEMALE; GLIOMA; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; PERFUSION IMAGING; TOMOGRAPHY, X-RAY COMPUTED;

EID: 79956126030     PISSN: 01956108     EISSN: 1936959X     Source Type: Journal    
DOI: 10.3174/ajnr.A2263     Document Type: Review

References (46)

1. Folkman J. The role of angiogenesis in tumor growth. Semin Cancer Biol 1992;3:65-71
2. Jain RK, Munn LL, Fukumura D. Dissecting tumour pathophysiology using intravital microscopy. Nat Rev Cancer 2002;2:266-76 (Pubitemid 37328780)
3. Law M, Young RJ, Babb JS, et al. Gliomas: predicting time to progression or survival with cerebral blood volume measurements at dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2008;247:490-98
4. Roberts HC, Roberts TP, Brasch RC, et al. Quantitative measurement of microvascular permeability in human brain tumors achieved using dynamic contrast-enhanced MR imaging: correlation with histologic grade. AJNR Am J Neuroradiol 2000;21:891-99 (Pubitemid 30262836)
5. Law M, Yang S, Babb JS, et al. Comparison of cerebral blood volume and vascular permeability from dynamic susceptibility contrast-enhanced perfusion MR imaging with glioma grade. AJNR Am J Neuroradiol 2004;25:746-55 (Pubitemid 38657655)
6. Ellika SK, Jain R, Patel SC, et al. Role of perfusion CT in glioma grading and comparison with conventional MR imaging features. AJNR Am J Neuroradiol 2007;28:1981-87 (Pubitemid 350174746)
7. Jain R, Ellika SK, Scarpace L, et al. Quantitative estimation of permeability surface-area product in astroglial brain tumors using perfusion CT and correlation with histopathologic grade. AJNR Am J Neuroradiol 2008;29:694-700 (Pubitemid 351571548)
8. Cairncross JG, Ueki K, Zlatescu MC, et al. Specific genetic predictors of chemotherapeutic response and survival in patients with anaplastic oligodendrogliomas. J Natl Cancer Inst 1998;90:1473-79 (Pubitemid 28482012)
9. Law M, Oh S, Johnson G, et al. Perfusion magnetic resonance imaging predicts patient outcome as an adjunct to histopathology: a second reference standard in the surgical and nonsurgical treatment of low-grade gliomas. Neurosurgery 2006;58:1099-107 (Pubitemid 43879544)
10. Leon SP, Folkerth RD, Black PM. Microvessel density is a prognostic indicator for patients with astroglial brain tumors. Cancer 1996;77:362-72 (Pubitemid 26023356)
11. Li VW, Folkerth RD, Watanabe H, et al. Microvessel count and cerebrospinal fluid basic fibroblast growth factor in children with brain tumours. Lancet 1994;344:82-86 (Pubitemid 24214134)
12. Weidner N. Intratumor microvessel density as a prognostic factor in cancer. Am J Pathol 1995;147:9-19
13. Cha S, Johnson G, Wadghiri YZ, et al. Dynamic, contrast-enhanced perfusion MRI in mouse gliomas: correlation with histopathology. Magn Reson Med 2003;49:848-55 (Pubitemid 36523471)
14. Aronen HJ, Pardo FS, Kennedy DN, et al. High microvascular blood volume is associated with high glucose uptake and tumor angiogenesis in human gliomas. Clin Cancer Res 2000;6:2189-200 (Pubitemid 30399184)
15. Plate KH, Breier G, Weich HA, et al. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 1992;359:845-48
16. Shweiki D, Itin A, Soffer D, et al. Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis. Nature 1992;359:843-45
17. Bhujwalla ZM, Artemov D, Natarajan K, et al. Reduction of vascular and permeable regions in solid tumors detected by macromolecular contrast magnetic resonance imaging after treatment with antiangiogenic agent TNP-470. Clin Cancer Res 2003;9:355-62 (Pubitemid 36109752)
18. Raatschen HJ, Simon GH, Fu Y, et al. Vascular permeability during antiangiogenesis treatment: MR imaging assay results as biomarker for subsequent tumor growth in rats. Radiology 2008;247:391-99
19. Provenzale JM, Mukundan S, Dewhirst M. The role of blood-brain barrier permeability in brain tumor imaging and therapeutics. AJR Am J Roentgenol 2005;185:763-67
20. Johnson JA, Wilson TA. A model for capillary exchange. Am J Physiol 1966;210:1299-303
21. Purdie TG, Henderson E, Lee TY. Functional CT imaging of angiogenesis in rabbit VX2 soft-tissue tumour. Phys Med Biol 2001;46:3161-75 (Pubitemid 34568065)
22. Lee TY, Purdie TG, Stewart E. CT imaging of angiogenesis. Q J Nucl Med 2003;47:171-87 (Pubitemid 37279154)
23. St Lawrence KS, Lee TY. An adiabatic approximation to the tissue homogeneity model for water exchange in the brain: I. Theoretical derivation. J Cereb Blood Flow Metab 1998;18:1365-77 (Pubitemid 28559684)
24. Lev MH, Ozsunar Y, Henson JW, et al. Glial tumor grading and outcome prediction using dynamic spin-echo MR susceptibility mapping compared with conventional contrast-enhanced MR: confounding effect of elevated rCBV of oligodendrogliomas [corrected]. AJNR Am J Neuroradiol 2004;25:214-21 (Pubitemid 38235298)
25. Law M, Yang S, Wang H, et al. Glioma grading: sensitivity, specificity, and predictive values of perfusion MR imaging and proton MR spectroscopic imaging compared with conventional MR imaging. AJNR Am J Neuroradiol 2003;24:1989-98 (Pubitemid 37444849)
26. Jain R, Gutierrez J, Narang J, et al. In vivo correlation of tumor blood volume and permeability with histological and molecular angiogenic markers in gliomas. AJNR Am J Neuroradiol. 2011;32:388-94
27. Kumar AJ, Leeds NE, Fuller GN, et al. Malignant gliomas: MR imaging spectrum of radiation therapy-and chemotherapy-induced necrosis of the brain after treatment. Radiology 2000;217:377-84
28. Chernov M, Hayashi M, Izawa M, et al. Differentiation of the radiation-induced necrosis and tumor recurrence after gamma knife radiosurgery for brain metastases: importance of multi-voxel proton MRS. Minim Invasive Neurosurg 2005;48:228-34 (Pubitemid 41392546)
29. Langleben DD, Segall GM. PET in differentiation of recurrent brain tumor from radiation injury. J Nucl Med 2000;41:1861-67
30. Covarrubias DJ, Rosen BR, Lev MH. Dynamic magnetic resonance perfusion imaging of brain tumors. Oncologist 2004;9:528-37 (Pubitemid 39332316)
31. Jain R, Scarpace L, Ellika S, et al. First-pass perfusion computed tomography: initial experience in differentiating recurrent brain tumors from radiation effects and radiation necrosis. Neurosurgery 2007;61:778-86, discussion 786-87
32. Kamiryo T, Lopes MB, Kassell NF, et al. Radiosurgery-induced microvascular alterations precede necrosis of the brain neuropil. Neurosurgery 2001;49:409-14, discussion 414-15
33. Barajas RF Jr, Chang JS, Segal MR, et al. Differentiation of recurrent glioblastoma multiforme from radiation necrosis after external beam radiation therapy with dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. Radiology 2009;253:486-96
34. Barajas RF, Chang JS, Sneed PK, et al. Distinguishing recurrent intra-axial metastatic tumor from radiation necrosis following gamma knife radiosurgery using dynamic susceptibility-weighted contrast-enhanced perfusion MR imaging. AJNR Am J Neuroradiol 2009;30:367-72
35. Jain R, Narang J, Schultz L, et al. Permeability estimates in histopathology proven treatment induced necrosis using perfusion CT: can these add to other perfusion parameters in differentiating from recurrent/progressive tumors? AJNR Am J Neuroradiol. 2011;32:658-63
36. Sugita Y, Terasaki M, Shigemori M, et al. Acute focal demyelinating disease simulating brain tumors: histopathologic guidelines for an accurate diagnosis. Neuropathology 2001;21:25-31 (Pubitemid 32280384)
37. Annesley-Williams D, Farrell MA, Staunton H, et al. Acute demyelination, neuropathological diagnosis, and clinical evolution. J Neuropathol Exp Neurol 2000;59:477-89 (Pubitemid 30368307)
38. Zagzag D, Miller DC, Kleinman GM, et al. Demyelinating disease versus tumor in surgical neuropathology: clues to a correct pathological diagnosis. Am J Surg Pathol 1993;17:537-45 (Pubitemid 23152591)
39. Prineas JW, MacDonald WI. Demyelinating diseases. In: Graham DI, Lantos PL, eds. Greenfield's Neuropathology. 6th ed. London, UK: Oxford University Press; 1997:814-46
40. Jain R, Ellika S, Lehman NL, et al. Can permeability measurements add to blood volume measurements in differentiating tumefactive demyelinating lesions from high grade gliomas using perfusion CT? J Neurooncol 2010;97:383-88
41. Yankeelov TE, Rooney WD, Huang W, et al. Evidence for shutter-speed variation in CR bolus-tracking studies of human pathology. NMR Biomed 2005;18:173-85 (Pubitemid 40716124)
42. Conturo TE, Akbudak E, Kotys MS, et al. Arterial input functions for dynamic susceptibility contrast MRI: requirements and signal options. J Magn Reson Imaging 2005;22:697-703 (Pubitemid 41741233)
43. Boxerman JL, Schmainda KM, Weisskoff RM. Relative cerebral blood volume maps corrected for contrast agent extravasation significantly correlate with glioma tumor grade, whereas uncorrected maps do not. AJNR Am J Neuroradiol 2006;27:859-67 (Pubitemid 44897737)
44. Johnson G, Wetzel SG, Cha S, et al. Measuring blood volume and vascular transfer constant from dynamic, T(2)*-weighted contrast-enhanced MRI. Magn Reson Med 2004;51:961-68 (Pubitemid 38580608)
45. Uematsu H, Maeda M. Double-echo perfusion-weighted MR imaging: basic concepts and application in brain tumors for the assessment of tumor blood volume and vascular permeability. Eur Radiol 2006;16:180-86 (Pubitemid 43103583)
46. Hara AK, Paden RG, Silva AC, et al. Iterative reconstruction technique for reducing body radiation dose at CT: feasibility study. AJR Am J Roentgenol 2009;193:764-71